Physician profile
Nathaniel J Moore
NPI 1275570301
$1,570.58
in general payments reported to CMS, 2019-2025
26 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $330 · 2021: $75.90 · 2022: $70.75 · 2023: $262 · 2024: $162 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $839.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Titan Pharmaceuticals, INC. | $294.02 | 2019-2020 | |
| Ethicon INC. | $130.59 | 2023 | Monarch Platform |
| Indivior INC. | $120.27 | 2019-2025 | Sublocade |
| Alkermes, INC. | $109.86 | 2020-2025 | Vivitrol |
| Merck Sharp & Dohme LLC | $105.51 | 2019-2022 | |
| Pfizer INC. | $89.12 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.84 | 2025 | Caplyta |
| Astellas Pharma US INC | $68.72 | 2025 | Veozah |
| Lilly USA, LLC | $59.42 | 2024-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.20 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $44.45 | 2021-2025 | Breztri |
| Otsuka America Pharmaceutical, INC. | $44.31 | 2025 | Rexulti |
| Aimmune Therapeutics, INC. | $42.53 | 2025 | Zenpep |
| Amgen INC. | $41.01 | 2023-2025 | Otezla, Repatha, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.94 | 2024-2025 | Relistor, Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $37.98 | 2023 | |
| Eisai INC. | $35.40 | 2020 | |
| Viiv Healthcare Company | $32.36 | 2024 | Apretude |
| Orexo US, INC. | $31.15 | 2019 | |
| Uswm, LLC | $29.57 | 2021-2022 | |
| Hologic Sales and Service, LLC | $29.03 | 2019 | |
| Braeburn INC. | $19.21 | 2025 | Brixadi |
| Clarus Therapeutics INC. | $18.08 | 2021 | |
| Exeltis, USA INC. | $16.25 | 2024 | Slynd |
| Novo Nordisk INC | $15.76 | 2025 | Ozempic, Rybelsus |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.